NEW YORK (GenomeWeb) – Inspirata announced today that it has acquired Precision Medicine Network (PMNI), a Boston-based service that connects healthcare providers, patients, and payors.
Key to the deal is PMNI's Crosswalk Insight: Oncology precision medicine knowledge visualization and decision support platform, Inspirata said. The cloud-based system provides access to a patient's diagnostic data including tumor images, as well as information on their disease's molecular pathways, FDA-approved targeted therapies, and relevant clinical research trials. Inspirata said it aims to integrate this platform with its Digital Pathology Cockpit software system and Cancer Information Data Trust database.
"Precision Medicine Network is a very strategic acquisition for us because the Crosswalk platform positions our Digital Pathology Cockpit to bridge the gap between anatomic pathology and a patient's tumor genes, molecular pathways, matching drugs, and relevant drug trials that they may be eligible for," Inspirata CEO Satish Sanan said in a statement.
Following the acquisition, PMNI Co-founder and Chief Medical Officer Mark Boguski will join Inspirata as senior vice president of precision medicine and strategic advisory board member. Additional terms of the transaction were not disclosed.